转移性肾细胞癌治疗研究进展

Progress in the treatment of metastatic renal cell carcinoma

转移性肾细胞癌 (mRCC)目前尚无治愈性措施。作者综述了近年来对mRCC预后指标和新的治疗方法如减瘤性肾切除、细胞因子、非清髓性干细胞移植、疫苗预致敏淋巴结细胞、抗血管生成及信号转导抑制剂等的研究进展。

Although there is currently no curative therapeutic modalities for metastatic renal cell carcinoma(mRCC), several investigational strategies have shown initial encouraging results. The data from randomized clinical trials seem to support the use of cytoreductive nephrectomy before systematic therapy in patients with mRCC. Novel immunotherapeutic approaches include nonmyeloablative stem cell transplantation and ex vivo-activated tumor-specific lymphocytes from vaccine-primed lymph node cells. Antiangiogenic strategies include therapies targeted at vascular endothelial growth factor(VEGF), its receptor and the downstream signaling of the VEGF receptor.